Small cell lung cancer (SCLC) is a malignant disease associated with a particularly high mortality rate. According to a new multicenter study, SCLC can be divided into several subgroups in terms of clinical behavior. These subtypes respond differently to chemotherapeutics and targeted drugs. This opens up possibilities for personalized treatment for this type of cancer as well.
